```html

Iatrogenic Cushing’s Syndrome

Overview

Iatrogenic Cushing’s syndrome (ICS) is a form of Cushing’s syndrome that results from prolonged exposure to high‑dose glucocorticoid medications prescribed for other medical conditions. The excess cortisol‑like effect is not caused by a tumor (as in endogenous Cushing’s) but by the drug itself.

Anyone who receives systemic glucocorticoids—oral, intravenous, intramuscular, or high‑dose topical preparations—can develop ICS. The syndrome is most common in adults, but children receiving long‑term steroids for asthma, rheumatic disease, or transplant prophylaxis are also at risk.

Prevalence: While exact numbers are difficult to capture, epidemiologic studies estimate that up to 5‑10 % of patients on chronic oral prednisone develop clinically evident Cushingoid features. In a 2020 systematic review, >30 % of patients on high‑dose inhaled steroids for severe asthma showed measurable cortisol suppression, a biochemical precursor to iatrogenic Cushing’s.

Symptoms

The clinical picture mirrors endogenous Cushing’s, because the underlying pathophysiology—excess glucocorticoid activity—is the same. Symptoms often appear gradually and may be misattributed to the underlying disease or aging.

Classic (most common) manifestations

• Central (truncal) obesity – increased abdominal fat with a “moon‑shaped” face.
• Facial rounding (moon face) – fullness of the cheeks and periorbital area.
• Buffalo hump – dorsocervical fat pad.
• Skin changes – thin, fragile skin, easy bruising, purple striae (especially on abdomen, thighs, and breasts).
• Muscle weakness – proximal myopathy leading to difficulty climbing stairs or lifting objects.
• Hypertension – systolic/diastolic >140/90 mmHg in many patients.
• Glucose intolerance or overt diabetes mellitus.
• Bone loss (osteoporosis) – increased fracture risk, especially vertebral compression fractures.
• Psychiatric effects – mood swings, irritability, anxiety, depression, or even psychosis.
• Immune suppression – frequent infections, delayed wound healing.

Additional or less common symptoms

• Fatigue and generalized malaise.
• Menstrual irregularities, decreased libido, erectile dysfunction.
• Facial acne and hirsutism (especially in women).
• Eye changes – cataracts, increased intra‑ocular pressure.
• Gastro‑intestinal ulcer disease.

Causes and Risk Factors

ICS is caused by exogenous glucocorticoids that mimic cortisol. The risk is related to dose, duration, route of administration, and individual susceptibility.

Common medication sources

• Oral prednisone, prednisolone, methylprednisolone, dexamethasone, or hydrocortisone.
• Intravenous or intramuscular bolus therapy (e.g., for acute exacerbations of asthma, severe allergic reactions).
• High‑dose inhaled corticosteroids (e.g., fluticasone > 500 µg/day) or long‑acting bronchodilator combinations.
• Topical potent steroids (clobetasol propionate, betamethasone dipropionate) applied over large body surface areas or under occlusion.
• Intra‑articular or epidural steroid injections—especially when repeated frequently.
• Systemic anti‑inflammatory agents that contain steroids (e.g., adrenal supplements in chemotherapy protocols).

Risk factors

• High cumulative dose: ≥ 5 mg prednisone equivalent daily for >3 months is a classic threshold, but even shorter courses at very high doses can cause CSI.
• Age: Elderly patients have reduced cortisol clearance.
• Body mass index (BMI): Obesity may amplify steroid‑induced fat redistribution.
• Comorbidities: Diabetes, hypertension, osteoporosis increase vulnerability.
• Genetic factors: Polymorphisms in glucocorticoid receptor genes can alter sensitivity.
• Concomitant CYP‑3A4 inhibitors: Drugs such as ketoconazole or ritonavir raise steroid levels.

Diagnosis

Diagnosing iatrogenic Cushing’s requires a careful history, physical exam, and targeted laboratory testing to confirm cortisol excess and rule out endogenous sources.

Step‑by‑step approach

1. History and medication review: Document all glucocorticoid products, doses, routes, and duration.
2. Physical examination: Look for hallmark signs (moon face, truncal obesity, striae).
3. Biochemical confirmation:
   • Serum cortisol – usually high or inappropriately normal.
   • 24‑hour urinary free cortisol (UFC) – elevated > 50 µg/24 h in most cases.
   • Late‑night salivary cortisol – loses its normal diurnal dip.
4. Adrenal suppression test: Low‑dose dexamethasone suppression test (1 mg overnight) will often fail to suppress cortisol in patients with substantial exogenous exposure.
5. Excluding endogenous disease: If the medication history is unclear, a ACTH measurement and MRI of the pituitary may be indicated to rule out a pituitary adenoma.

Imaging (when needed)

Imaging Modality	Indication
DEXA scan	Baseline bone mineral density assessment.
CT/MRI of abdomen	Only if an adrenal mass is suspected (rare in pure iatrogenic cases).

Treatment Options

The cornerstone of therapy is to gradually reduce the glucocorticoid exposure while managing the underlying disease that required steroids in the first place.

1. Tapering the offending steroid

• Gradual reduction: Decrease dose by 5‑10 % every 1‑2 weeks, depending on the starting dose and patient tolerance.
• Physiologic replacement: For patients on long‑term high doses, transition to a physiologic hydrocortisone regimen (≈ 10‑20 mg/day) before complete withdrawal.
• Monitoring: Watch for adrenal insufficiency symptoms (fatigue, nausea, hypotension) during taper.

2. Managing specific complications

• Hyperglycemia: Lifestyle measures + metformin or insulin if needed (follow ADA guidelines).
• Hypertension: ACE inhibitors, ARBs, calcium‑channel blockers as first‑line per JNC‑8.
• Osteoporosis: Calcium 1,200 mg + vitamin D 800‑1,000 IU daily, plus bisphosphonate (alendronate 70 mg weekly) for ≥ 3 months of steroid use.
• Weight management: Low‑glycemic diet, regular aerobic exercise (150 min/week).
• Psychiatric symptoms: Referral to mental‑health professional; short‑term low‑dose antidepressants or anxiolytics if indicated.

3. Pharmacologic agents to counteract glucocorticoid effects (when taper is not possible)

• Mifepristone (RU‑486): Glucocorticoid receptor antagonist approved for hyperglycemia secondary to Cushing’s; off‑label use in refractory iatrogenic cases.
• Ketoconazole or metyrapone: Inhibit cortisol synthesis—primarily used in endogenous disease, but occasionally employed when withdrawal is contraindicated.

4. Surgical or procedural interventions

Rarely required for iatrogenic disease, but patients may need:

• Adrenalectomy if an adrenal adenoma develops secondary to chronic ACTH suppression.
• Joint injections or nerve blocks as alternative pain‑control strategies to avoid systemic steroids.

Living with Iatrogenic Cushing’s Syndrome

Even after steroid taper, many patients experience lingering effects. The following strategies can improve quality of life.

Daily management tips

• Nutrition: Emphasize a Mediterranean‑style diet rich in fruits, vegetables, whole grains, lean protein, and healthy fats. Limit processed sugars to reduce glucose spikes.
• Physical activity: Strength‑training 2‑3 times per week improves muscle weakness; weight‑bearing exercises support bone health.
• Sleep hygiene: Aim for 7‑9 hours; maintain a consistent bedtime routine to counteract cortisol rhythm disruption.
• Medication reconciliation: Keep an up‑to‑date list of all steroids (including creams and inhalers) and share it with every healthcare provider.
• Stress management: Mind‑body techniques (yoga, meditation) can mitigate the neuro‑psychiatric impact of excess cortisol.
• Regular monitoring: Annual DEXA scans, blood pressure checks, fasting glucose/HbA1c, and ophthalmologic exams.

Support resources

• National Cushing’s Foundation (cushings.org) – patient education and support groups.
• American Diabetes Association – guidance on steroid‑induced hyperglycemia.
• Local osteoporosis clinics for bone‑density management.

Prevention

Prevention starts with judicious prescribing and patient education.

For Healthcare Professionals

• Prescribe the lowest effective glucocorticoid dose for the shortest duration possible.
• Prefer inhaled, topical, or intra‑articular formulations when clinically appropriate.
• Use “steroid‑sparing” agents (e.g., methotrexate, biologics) for chronic inflammatory diseases.
• Document steroid dose in prednisone‑equivalent units to aid future tapering.
• Educate patients about signs of Cushingoid changes and schedule follow‑up labs (e.g., fasting glucose) after 2‑4 weeks of therapy.

For Patients

• Ask your prescriber whether a lower‑dose or non‑steroid alternative exists.
• Never abruptly stop steroids—always follow a taper plan.
• Report new weight gain, facial rounding, or easy bruising promptly.
• Maintain a medication diary, especially if using multiple steroid-containing products.

Complications

If left untreated, the excess glucocorticoid environment can cause serious, often irreversible health problems.

• Severe hyperglycemia/diabetes mellitus – increased cardiovascular risk.
• Hypertensive heart disease – left ventricular hypertrophy, heart failure.
• Osteoporotic fractures – especially vertebral compression fractures.
• Infections – bacterial, viral, fungal; increased risk of opportunistic infections like Pneumocystis jirovecii.
• Psychiatric disorders – major depressive disorder, psychosis, suicidal ideation.
• Skin thinning and poor wound healing – may complicate surgeries.
• Adrenal insufficiency after abrupt discontinuation, which can be life‑threatening.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, American Diabetes Association, Endocrine Society clinical practice guidelines, peer‑reviewed articles up to May 2024.

```